Developing the best pulsed field ablation system in the world isn’t cheap, and Kardium’s new $250M financing round signals that the company now has enough funding to pursue that mission to its fullest.
- Kardium is the developer of the Globe Pulsed Field System which uses an innovative design to provide ablation for atrial fibrillation.
- The Globe System consists of a 122-electrode array catheter and software that enables rapid pulmonary vein isolation, high-definition mapping, and ablation anywhere in the atrium all with the same catheter.
- The company had previously raised $220M over five funding rounds, so the new investments more than double its total raised in just one go (Now $470M).
The fresh funding round follows impressive clinical data from Kardium’s PULSAR study presented at HRS 2025 that demonstrated the Globe System’s effectiveness and safety.
- The Globe System had a 100% acute procedural success rate.
- 78% of paroxysmal AF patients were free from atrial arrhythmia at 1 year.
- The procedure only took 96 minutes on average, with ablation lasting 25.5 minutes.
- On top of that, the study showed no device-related primary safety events.
Kardium now aims to use the funding to fully build out its regulatory approval process and commercialization infrastructure.
- The company will establish a clinical support and commercial team while expanding its manufacturing facilities in preparation for the Globe System’s launch later this year.
- It will also enable Kardium to run further clinical research for additional applications and expanded indications for its PFA platform.
Considering the hype around PFA, Kardium’s newfound financial base will help support its competition with industry giants that already have regulatory approval like…
- Medtronic’s PulseSelect system (CE mark and U.S. FDA approval).
- Boston Scientific’s Farapulse system (CE mark and U.S. FDA approval).
- Johnson & Johnson MedTech’s Varipulse platform (CE mark and U.S. FDA approval).
- Abbott’s Volt Pulsed Field Ablation System (CE Mark approval).
The Takeaway
It’s rare to see an independent medtech company perform so well in the early stages of product development, so Kardium’s trial results and funding success speak volumes to investor confidence. How Kardium will perform in a crowded market remains to be seen, but early data and investor funding both suggest a lot of potential on the horizon.
